TNFRSF17 and Miyoshi myopathy: A preclinical study evaluating bispecific CAR-T cells simultaneously targeting both BCMA and SLAMF7 on MM cells showed promising results to prevent antigen escape and better control MM cells heterogeneously expressing these antigens [141].